🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Aarti Pharmalabs Limited AARTIPHARM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.aartipharmalabs.com
Company Profile ↓
₹858.80
+0.79% 1Y
Mkt Cap₹7,785.69 Cr
P/E44.61
P/B2.93
Div. Yield0.58%
52W High₹937.51
52W Low₹591.95
Book Value₹234.35
EPS (TTM)₹19.25

Company Overview

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.

Why Investors Should Care

Healthy Margins

Operating margin of 16.4% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.36.

Recent Developments

  • Mar 2026 Revenue of ₹1,819.44 Cr (-14.0% YoY); net profit ₹174.71 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -14.0%, earnings -35.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR -2.0%, profit CAGR -3.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-2.05%
1 Year:-13.98%

Compounded Profit Growth

5 Years:-3.35%
1 Year:-35.86%

Stock Price Performance

1 Year:+0.79%
6 Months:+22.66%
3 Months:+37.35%
1 Month:+24.06%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 77% of range
₹591.95 ₹937.51
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.67 · Neutral
Price Performance
1M+24.06%
3M+37.35%
6M+22.66%
1Y+0.79%
Valuation vs Sector

P/E of 44.61 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -2.0% CAGR over 5 years.
  • Earnings shrank at -3.3% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
44.61
Industry PE
41.64
Forward P/E
33.68
PEG Ratio
-
Book Value
₹234.35
Price to Book
2.93
P/S
3.42
EV/EBITDA
17.41
Dividend Yield
0.58%

Growth (CAGR)

Revenue 5Y
-2.05%
Profit 5Y
-3.35%
Revenue (YoY)
-13.98%
Earnings (YoY)
-35.86%

Profitability & Returns

ROCE
11.00%
ROE
8.22%
ROA
5.02%
Profit Margin
9.60%
Op Margin
16.38%
Gross Margin
54.12%
EPS (Latest Qtr)
₹6.74
EPS (TTM)
₹19.25

Balance Sheet & Liquidity

Debt/Equity
0.36
Quick Ratio
0.81
Current Ratio
1.49
Debt
₹754.36 Cr
Total Assets
₹3,481.71 Cr
Current Assets
₹1,397.29 Cr
Working Capital
₹459.72 Cr

Ownership

Promoter Holding
44.10%
Chg in Prom Hold
-0.12%
FII / Inst Holding
12.62%
Chg in FII Hold
0.13%

Financial Snapshot

Enterprise Value
₹7,785.69 Cr
Total Revenue (TTM)
₹1,819.44 Cr
EBITDA
₹384.16 Cr
Free Cash Flow
₹-186.38 Cr
Operating Cash Flow
₹261.93 Cr
Shares Outstanding
₹9.07 Cr
Gross Margin
54.12%
Payout Ratio
20.78%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AARTIPHARM Aarti Pharmalabs Limited NSEPHARMA 858.80 44.61 ₹7,785.69 Cr 0.58% 11.00% 8.22% -2.05% -3.35%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 485.00 Cr458.00 Cr440.00 Cr449.00 Cr506.00 Cr555.00 Cr-538.00 Cr563.78 Cr386.19 Cr418.33 Cr432.27 Cr582.64 Cr
Cost of Revenue --------259.65 Cr169.41 Cr209.78 Cr172.66 Cr283.02 Cr
Gross Profit --------304.13 Cr216.79 Cr208.56 Cr259.62 Cr299.62 Cr
Operating Expenses 405.00 Cr373.00 Cr352.00 Cr353.00 Cr388.00 Cr459.00 Cr-409.00 Cr181.32 Cr144.34 Cr158.61 Cr185.93 Cr197.66 Cr
Operating Income 64.00 Cr68.00 Cr70.00 Cr77.00 Cr99.00 Cr76.00 Cr-106.00 Cr122.81 Cr72.45 Cr49.95 Cr73.69 Cr101.97 Cr
EBITDA 80.00 Cr85.00 Cr88.00 Cr96.00 Cr118.00 Cr96.00 Cr-129.00 Cr144.02 Cr95.04 Cr74.13 Cr104.07 Cr126.70 Cr
Interest Expense 6.00 Cr4.00 Cr4.00 Cr4.00 Cr5.00 Cr5.00 Cr-10.00 Cr6.58 Cr6.79 Cr10.67 Cr12.58 Cr16.86 Cr
Pretax Income 59.00 Cr64.00 Cr67.00 Cr74.00 Cr96.00 Cr74.00 Cr-101.00 Cr114.62 Cr65.45 Cr38.69 Cr62.87 Cr81.68 Cr
Tax Provision 15.93 Cr16.64 Cr15.41 Cr21.46 Cr30.72 Cr18.50 Cr-26.26 Cr26.28 Cr15.95 Cr10.77 Cr14.91 Cr20.55 Cr
Net Income 43.00 Cr47.00 Cr52.00 Cr53.00 Cr65.00 Cr55.00 Cr-74.00 Cr88.34 Cr49.50 Cr27.92 Cr47.96 Cr61.12 Cr
Diluted EPS 4.735.205.725.827.206.12-8.169.745.463.085.296.74

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 0-1,936.00 Cr1,815.51 Cr2,115.07 Cr1,819.44 Cr
Cost of Revenue --1,253.97 Cr1,113.06 Cr1,076.65 Cr834.83 Cr
Gross Profit --682.04 Cr702.44 Cr1,038.42 Cr984.61 Cr
Operating Expenses 0-402.53 Cr389.63 Cr660.95 Cr686.53 Cr
Operating Income 0-279.51 Cr312.81 Cr377.47 Cr298.08 Cr
EBITDA 0-344.37 Cr390.94 Cr474.49 Cr384.16 Cr
Interest Expense 0-21.05 Cr17.21 Cr26.90 Cr46.90 Cr
Pretax Income 0-260.77 Cr300.49 Cr360.69 Cr232.92 Cr
Tax Provision --67.28 Cr83.59 Cr88.28 Cr58.21 Cr
Net Income 0-193.49 Cr216.90 Cr272.40 Cr174.71 Cr
Diluted EPS --21.3523.9330.0419.25

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 0-2,244.02 Cr2,582.11 Cr2,906.41 Cr3,481.71 Cr
Current Assets --1,163.01 Cr1,345.64 Cr1,322.17 Cr1,397.29 Cr
Cash & Equivalents --12.12 Cr23.63 Cr6.73 Cr8.53 Cr
Inventory --602.04 Cr642.86 Cr587.58 Cr640.31 Cr
Receivables --450.10 Cr519.34 Cr575.40 Cr583.32 Cr
Total Liabilities --685.54 Cr825.07 Cr916.50 Cr1,357.10 Cr
Current Liabilities --600.62 Cr694.39 Cr657.05 Cr937.57 Cr
Long Term Debt --18.35 L3.88 L111.26 Cr185.81 Cr
Total Debt 0-215.31 Cr285.25 Cr420.82 Cr754.36 Cr
Total Equity 25.00 L-1,558.49 Cr1,757.04 Cr1,989.91 Cr2,124.60 Cr
Shares Outstanding --9.06 Cr9.06 Cr9.06 Cr9.07 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 0-250.12 Cr216.35 Cr330.14 Cr261.93 Cr
Investing Cash Flow 0--157.80 Cr-214.56 Cr-412.48 Cr-430.72 Cr
Financing Cash Flow 0--163.46 Cr9.72 Cr65.43 Cr170.58 Cr
Capital Expenditure 0--119.66 Cr-198.79 Cr-443.88 Cr-448.31 Cr
Free Cash Flow 0-130.46 Cr17.57 Cr-113.74 Cr-186.38 Cr
Net Change in Cash 0--71.15 Cr11.51 Cr-16.90 Cr1.80 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --35.2%38.7%49.1%54.1%
Operating Margin % --14.4%17.2%17.8%16.4%
Net Margin % --10.0%11.9%12.9%9.6%
ROE % 0.0%-12.4%12.3%13.7%8.2%
ROCE % --17.0%16.6%16.8%11.7%

Shareholding Pattern

Insiders
44.10%
Institutions
12.62%
Public Float
22.58%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AARTIPHARM

Google News Fri, 13 Feb 2026

Unpleasant Surprises Could Be In Store For Aarti Pharmalabs Limited's (NSE:AARTIPHARM) Shares - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQbU9EUDBaNERBMXFXS3dsYjY4V0tZN3U1UUpwWXpITjJMZmpxVS1WN2xRMzlmQWpTQW5QS2d2bFFhQW0zTjR0RV9qdGpEZl9XYVdnanZNc2tUanpRQ002SkhOZHlnS0I4U3hkZ0g5NS1LTkgwWERLMllQc0VGckFsTkg2QUlOTnA0SVBaTm…

Google News Sun, 07 Jun 2026

AARTIPHARM Q2 2026 Earnings: Revenue Decline of 14% Drags EPS to ₹19.25; Stock Sheds 2.4% - New Analyst Coverage - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOWkRxTVpjVFctRG1IZXpKS0F1Sk9Tb1FqRFY2Q3dqUk5aTjduNzRpWWhVLUktVjNmT0JzSHdpN0FJdllKWW9xV2lLa1BJM3V6TXhXeVpLdURSbUR0bGZLelROY091U1pRcl9CZUxtQjZDTmpMbXlrLWpBSnAxVHl2VDdTOWtIclMxalAxMG…

Google News ue, 11 Aug 2026

AARTIPHARM Standalone June 2026 Net Sales at Rs 534.59 crore, up 42.44% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQbWZQZUF3OXgzamNtcTdKejNBWlZSSkZiRmIwSDhTTmo2cXI4WlgwcTUwVVlsdHliYmxDRGwwUTVXeFhzcnBCclFSZHczZExkbDFZNG5NdG5vQ08zaEdCLVRFLXJHbG1fZTZ0bTJ4a1NESUlqOUNWVmdHZl9OdnBJMHdBRlNEd0NTLXljU0…

Google News Mon, 01 Jun 2026

Aarti Pharmalabs Insider Ups Holding During Year - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNVXQzSnI2WU5IbjFiVUJ3LWpibnBGUFRFNXBTQVhnNmNjTndtYzJPbE1hQWo3RVRCU2FvMUNQWWtvSXRGS21ieDh4QWRtNWtVRWNGaWxQZHZUQXpVLUdRb3huYU1ka1NrLXlEQzM1bF9yWG44M3ZVbUhiV203QjRGd3FXdlc0X3VQdWZmUE…

Google News Mon, 10 Aug 2026

Aarti Pharmalabs shares hit 20% upper circuit as Q1 net profit surges 65% YoY to Rs 76 crore - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxQWF9IUk40MDV1cy00cEhYUGlYald2V0QyQllEODBaTXhIZ0JSbkEwejBVdWJBbjBSMjg5Qm9RRnNRQ1Y0MmJFX3NkWVhiQ2d6c0lQMGVlUUsybTBidDU1Vm05dHNJRzdjdk1aRXV6N2tKY2NucGQ5SmQwTkRrNXhwWFA1U0hVLXVHQXNwYm…

Google News hu, 04 Jun 2026

Aarti Pharmalabs Limited (AARTIPHARM): Stock Rallies 3.5% on Positive Momentum, Approaches Key Resistance - Equal Weight ETF - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxObHlwRzZxajhTU1dKVlY5TDlPSWNTci05aHFPYUNQbDdFdFJZVmRrT0dyaUFfTTNoUGNDb1p0ZWhuSng4QS1zckxmVVZtaGhTMk5JYTYxUVhEa05EQWZNYkJYVXhuQTJ2N2RxZHZGS0RmX3BkeEtjWGM4REQzLW5JUV9oMGxCVHdqQk9KN3…

AARTIPHARM — Frequently Asked Questions

What is the current share price of Aarti Pharmalabs Limited (AARTIPHARM)?

As of 2026-09-08 04:53 IST, Aarti Pharmalabs Limited (AARTIPHARM) trades at ₹858.80 on NSE. Its 52-week range is ₹591.95 to ₹937.51.

What is the market capitalisation of AARTIPHARM?

Aarti Pharmalabs Limited (AARTIPHARM) has a market capitalisation of ₹7,785.69 Cr on NSE.

What is the P/E ratio of AARTIPHARM?

AARTIPHARM trades at a trailing price-to-earnings (P/E) ratio of 44.61. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.93.

Does AARTIPHARM pay a dividend?

Aarti Pharmalabs Limited (AARTIPHARM) currently offers a dividend yield of 0.58%.

What is the return on equity (ROE) of AARTIPHARM?

AARTIPHARM has a return on equity (ROE) of 8.22%. Its return on capital employed (ROCE) is 11.00%.

Is AARTIPHARM a good stock to buy?

This page provides a data-driven analysis of Aarti Pharmalabs Limited (AARTIPHARM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space